07/13/2020 12:00 AM EDT
Source: European Union, European Centre for Disease Prevention and Control (ECDC). Published: 7/13/2020. This four-page report on zoonotic influenza cases is based on data for 2019 retrieved on January 31, 2020. No human cases of avian influenza were reported in the European Union/European Economic Area. Sporadic human cases of avian influenza A(H5N6) and A(H9N2) were reported. (PDF)
07/13/2020 12:00 AM EDT
Source: European Union, European Centre for Disease Prevention and Control (ECDC). Published: 7/13/2020. This nine-page report discusses study findings that raise concern about the pandemic potential of swine influenza viruses, which are already able to replicate successfully in human tissue and transmit through droplets between ferrets, being a model for human-to-human transmission. It provides information about other related risk assessments and studies. (PDF)
07/13/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 7/13/2020. The eight-page, three-module COVID-19 Rapid Core Case Report Form (CRF) is designed to collect data obtained through examination, interview, and review of hospital notes. Data may be collected prospectively or retrospectively. (PDF)
07/13/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 7/13/2020. This 13-page Pregnancy Module Case Report Form (CRF-P) should be completed for pregnant women or recently pregnant women who delivered within 21 days from onset of COVID-19 symptoms. Data may be collected retrospectively if the patient data are obtained after the admission date. (PDF)
07/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/10/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a Molecular LDT COVID-19 Authorized Test called the BMC-CReM COVID-19 Test that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
07/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/10/2020. This four-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the gammaCore Sapphire CV during the coronavirus disease 2019 (COVID-19) pandemic. The gammaCore Sapphire CV is intended for acute use at home or in healthcare settings to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, using non-invasive vagus nerve stimulation (VNS) on either side of the patient’s neck during the COVID-19 pandemic. (PDF)
07/10/2020 12:00 AM EDT
Source: World Health Organization (WHO). Published: 7/10/2020. This risk assessment spreadsheet tool for generic events has been updated to reflect new WHO guidance and new evidence on both COVID-19 and mass gatherings, as well as feedback from end-users. The Decision Tree is now built into the tool, and a new tab dedicated to Risk Communication has been added. The expanded tool now includes six tabs: 1. Instructions; 2. Decision Tree; 3. Risk Evaluation; 4. Risk Mitigation; 5. Decision Matrix; and 6. Risk Communication. (PDF)
07/10/2020 12:00 AM EDT
Source: U.S. Department of Health and Human Services (HHS). Published: 7/10/2020. This web page contains state testing plans that are part of the government response to the COVID-19 pandemic. These plans set specific targets for COVID-19 testing in each jurisdiction. (Text)
07/09/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/9/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a Molecular LDT COVID-19 Authorized Test called the SARS-CoV-2 RNA DETECTR Assay that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
07/09/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/9/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Real-Q 2019-nCoV Detection Kit. The Real-Q 2019-nCoV Detection Kit is authorized for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
07/09/2020 12:00 AM EDT
Source: ADA [Americans with Disabilities Act] National Network. Published: 7/9/2020. This one-hour, 28-minute presentation focuses on plans for fire season and specifically addresses California's efforts regarding practicing integrated emergency communication, transportation/evacuation, and sheltering in a COVID-19 environment. Learning objectives include understanding effective techniques on how to achieve key emergency preparedness goals during the COVID-19 pandemic. (Video or Multimedia)
07/09/2020 12:00 AM EDT
Source: Congressional Research Service [Library of Congress] (CRS). Published: 7/9/2020. This six-page report discusses the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule’s application to digital contact tracing during the COVID-19 pandemic, the interaction of the HIPAA Privacy Rule with mobile application contact tracing, and other federal laws that regulate data privacy. (PDF)
07/08/2020 12:00 AM EDT
Source: Office of the Assistant Secretary for Preparedness and Response [U.S. Department of Health and Human Services] (HHS ASPR). Published: 7/8/2020. The audience for the information on this Web page includes national, state, and community-based organizations (CBOs), human/social services providers, state and local government agencies, food banks, low-income housing providers, community health centers, and other leaders in similar settings who are responsible for developing and putting into action care continuity policies and programming during and after COVID-19. (Text)
07/08/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/8/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a Molecular LDT COVID-19 Authorized Test called the CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
07/08/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/8/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Diazyme DZ-Lite SARS-CoV-2 IgG CLIA Kit. The Diazyme DZ-Lite SARS-CoV-2 IgG CLIA Kit is authorized for the detection of IgG antibodies to SARS-CoV-2 in human serum or plasma (potassium EDTA, disodium EDTA and lithium heparin). (PDF)
07/08/2020 12:00 AM EDT
Source: U.S. Department of Health and Human Services (HHS). Published: 7/8/2020. This five-page fact sheet, published with the Federal Emergency Management Agency (FEMA), provides an overview of key practices and resources to help consumers to understand approved and authorized use of respirators, to avoid purchasing fraudulent products, and to report fraud or potentially fraudulent distributors, resellers, or other suppliers during the COVID-19 pandemic. (PDF)
07/08/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention, Office of Infectious Diseases (CDC OID). Published: 7/8/2020. This overview was created for healthcare workers in non-U.S. healthcare settings and non-U.S. national government officials working on the COVID-19 response. The information draws from CDC and World Health Organization guidance documents and infection prevention and control (IPC) priorities for the response to COVID-19 in healthcare settings, and includes information that can be used in non-U.S. contexts. (Text)
07/08/2020 12:00 AM EDT
Source: National Institutes of Health (NIH). Published: 7/8/2020. This one-hour, 10-minute presentation discusses what is new in the pathogenesis of SARS-CoV-2 and how this affected the decision-making processes on the management and treatment of SARS-CoV-2 infection during the COVID-19 pandemic in New York City. Even in the absence of data and insufficient knowledge of what may or may not work, the Mount Sinai Health System created treatment guidelines that were updated frequently based on physicians' observations and information gathered from multiple disciplines across the system. (Video or Multimedia)
07/07/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the AMPIPROBE SARS-CoV-2 Test System. The AMPIPROBE SARS-CoV-2 Test System is authorized for use with upper respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
07/07/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the CareStart™ COVID-19 MDx RT-PCR test. The CareStart™ COVID-19 MDx RT-PCR test is authorized for use with upper respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
07/07/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of a Molecular LDT COVID-19 Authorized Test called the Gene By Gene SARS-CoV-2 Detection Test that has been issued an Emergency Use Authorization (EUA) by the FDA. The Molecular LDT COVID-19 Authorized Test is authorized for use on certain respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. (PDF)
07/07/2020 12:00 AM EDT
Source: National Academy of Medicine (NAM). Published: 7/7/2020. Sessions in this three-hour workshop include Patient and Family Engagement During COVID-19, which explores opportunities to engage patients and families in care settings during the pandemic, and focuses on identifying solutions to the continued and existing gaps on engagement that are especially critical to address at this time. Another session discusses System and Policy-Level Strategies to Address Health and Health Care Equity. (Video or Multimedia)
07/01/2020 12:00 AM EDT
Source: National Institutes of Health (NIH). Published: 7/2020. This 38-page NIH-wide COVID-19 strategic plan provides a framework for accelerating the development of COVID-19 therapeutic interventions, vaccines, and diagnostics. NIH will carry out this mission by improving, advancing, and optimizing COVID-19-related research in five key areas: fundamental knowledge, detection and diagnosis, treatment, prevention, and health disparities. (PDF)
07/01/2020 12:00 AM EDT
Source: Public Health Agency of Canada (PHAC). Published: 7/2020. This 108-page report provides a detailed assessment of antimicrobial resistance (AMR) in Canada. It also provides recent information on the amount of antimicrobials used in humans and animals, as antimicrobial use is one of the key drivers of AMR. (PDF)
06/10/2020 12:00 AM EDT
Source: U.S. Department of Veterans Affairs (VA). Published: 6/10/2020. The COVID-19 crisis is highlighting the potential value of virtual modalities for supporting remote access to care. This one-hour, five-minute webinar provides an overview of three recent research projects focused on the use of technology to support access to care. Presenters discuss the use of My HealtheVet’s Secure Messaging in homeless Veterans, a mobile app for PTSD combined with clinician support, and tablets to support telehealth among Veterans who report barriers to accessing in-person care. (Video or Multimedia)
06/01/2020 12:00 AM EDT
Source: United Nations Office for the Coordination of Humanitarian Affairs, Inter-Agency Standing Committee (IASC). Published: 6/2020. This nine-page document provides an overview of the factors that may put persons with disabilities at heightened risk in the COVID-19 pandemic and response in humanitarian settings, and proposes actions to address these risks. It draws on the IASC Guidelines on the Inclusion of Persons with Disabilities in Humanitarian Action, applying these to the COVID-19 pandemic. (PDF)
05/21/2020 12:00 AM EDT
Source: U.S. Department of Veterans Affairs (VA). Published: 5/21/2020. This one-hour, five-minute presentation discusses the role of behavioral change, as well as various whole health and complementary and integrative health modalities that have preliminary evidence for enhancing immune function during the COVID-19 pandemic. It reviews evidence for sleep, exercise, and stress reduction for improving immune function. The intended audience is a broad interdisciplinary audience of VA and non-VA clinicians and researchers. (Video or Multimedia)
.png)
No hay comentarios:
Publicar un comentario